has signed a US national distribution agreement with speciality pharmacy Superior Biologics to sell the former’s Humira biosimilar at $995 per carton of two 40mg autoinjectors.
This cost is at a sharp discount from two 鈥檚 originator biologic Humira 40mg syringes, which cost $6,922.
In June 2023, Coherus explored a partnership with billionaire Mark Cuban鈥檚 online pharmacy Cost Plus Drugs, with a slightly higher price of $1,138 for two 40mg Yusimry autoinjectors. The deal did not cover additional charges for shipping and dispensing, and health insurance providers not providing coverage for the prescription.
Humira is a tumour necrosis factor (TNF) blocker that is indicated for various adult and paediatric conditions, including various forms of arthritis, Crohn鈥檚 disease, and ulcerative colitis. The therapy was AbbVie鈥檚 blockbuster drug with sales of $21.2bn in 2022.
GlobalData estimates the market for Humira biosimilars to reach is expected to reach $514.4m in 2023 across the seven major pharmaceutical markets (US, France, Germany, Italy, Spain, UK, and Japan). 鈥檚 Amjevita, Humira biosimilar, was the first to capitalise on this having started its US roll-out in January this year.
Still, the Humira biosimilars are expected to face market resistance in the US due to how certain insurers cover drug contracts, and the reluctance of both doctors and patients to switch to the biosimilar in some conditions. In 2025, GlobalData forecasts to remain a market leader, and Yusimry to have global sales of $436m in 2025.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataGlobalData is the parent company of Pharmaceutical Technology.
Coherus CEO Denny Lanfear said: 鈥淐oherus is pleased to work with Superior Biologics for nationwide distribution of Yusimry, providing patients and their plan sponsors access to a high-quality, safe, and effective treatment at significant savings compared to Humira.
鈥淭hrough this unique distribution partnership, we can bring Yusmiry immediately to patients throughout the United States.鈥�
